Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Pioglitazone + Metformin;   Drug: Placebo Oral Tablet
Sponsor:   Sun Yat-sen University
Recruiting - verified June 2017

Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: CSII followed by Lina+MET;   Drug: CSII followed by Lina;   Drug: CSII followed by MET;   Drug: CSII alone
Sponsors:   Sun Yat-sen University;   Nanfang Hospital of Southern Medical University;   Guangdong General Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Zhujiang Hospital;   Guangzhou First People's Hospital;   The Third Affiliated Hospital of Guangzhou Medical University;   The Third Affiliated Hospital of Southern Medical University;   Guangdong Provincial Hospital of Traditional Chinese Medicine
Not yet recruiting - verified June 2017

Corazon de la Familia (Heart of the Family)

Conditions:   Risk Reduction Behavior;   Diabetes Mellitus, Type 2;   Cardiovascular Diseases
Interventions:   Behavioral: Family-focused intervention arm;   Behavioral: Individual-focused intervention arm
Sponsors:   University of Kentucky;   National Institute of Nursing Research (NINR);   National Institutes of Health (NIH)
Not yet recruiting - verified June 2017

Serum METRNL Concentration in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Chungnam National University Hospital
Completed - verified June 2017

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2017

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Digoxin
Sponsor:   Theracos
Not yet recruiting - verified June 2017

Inspiratory Muscle Training on Glycemic Control in Individuals With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Device: Inspiratory muscle training.;   Device: Placebo inspiratory muscle
Sponsor:   Hospital de Clinicas de Porto Alegre
Not yet recruiting - verified June 2017

Impact of a Multidisciplinary Therapeutic Education Program Being Set up for Patients With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Patient Education as Topic
Intervention:   Other: Treatment adequacy score
Sponsor:   Groupe Hospitalier Pitie-Salpetriere
Completed - verified June 2017

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

Conditions:   Pre Diabetes;   Obesity
Interventions:   Behavioral: MapTrek;   Device: Fitbit
Sponsors:   Philip Polgreen;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2017

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Conditions:   Type2 Diabetes Mellitus;   Cardiovascular Diseases
Interventions:   Drug: Canagliflozin 300mg;   Drug: Placebo
Sponsors:   Devjit Tripathy;   Janssen Scientific Affairs, LLC
Not yet recruiting - verified June 2017

Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)

Condition:   Type2 Diabetes
Interventions:   Dietary Supplement: Diet;   Other: cold exposure;   Radiation: 18FDG;   Radiation: 11C-acetate;   Radiation: [3-3H]-glucose;   Other: [U-13C]-palmitate;   Other: 2H-Glycerol;   Device: MRI/MRS;   Device: Electromyogram (EMG);   Device: DXA;   Device: Indirect calorimetry
Sponsors:   Université de Sherbrooke;   McMaster University;   University of Ottawa
Recruiting - verified June 2017

Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Dietary Supplement: Moringa oleifera tea
Sponsor:   Titilayo O Fakeye
Completed - verified June 2017

Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

Condition:   T2D
Interventions:   Dietary Supplement: Peanut;   Dietary Supplement: Control
Sponsor:   Harvard School of Public Health
Recruiting - verified June 2017

GLP1-imaging Before and After Bariatric Surgery

Conditions:   Diabetes Mellitus, Type 2;   Bariatric Surgery Candidate
Intervention:   Radiation: 68Ga-NODAGA-exendin-4 PET/CT
Sponsors:   Radboud University;   Rijnstate Hospital
Recruiting - verified May 2017

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Conditions:   Cardiovascular Diseases;   Mortality;   Type 2 Diabetes Mellitus;   Cognitive Decline;   Mental Well-being;   Kidney Function
Interventions:   Behavioral: Dietary intake;   Behavioral: Lifestyle factors;   Biological: Blood biomarkers;   Biological: Health;   Genetic: DNA;   Biological: Mental well-being
Sponsor:   Wageningen University
Active, not recruiting - verified June 2017

The Cork and Kerry Diabetes and Heart Disease Study (Phase II) Mitchelstown Cohort

Conditions:   Cardiovascular Diseases;   Diabetes;   Obesity;   Hypertension;   Dyslipidemia;   Metabolic Syndrome;   Diet Habit;   Life Style;   Physical Activity;   Smoking
Intervention:  
Sponsors:   University College Cork;   Livinghealth Clinic Mitchelstown
Completed - verified June 2017

Morning Light Treatment to Improve Glucose Metabolism

Conditions:   PreDiabetes;   Circadian Dysregulation
Interventions:   Other: Bright Light;   Other: Dim Light
Sponsors:   Northwestern University;   Rush University
Not yet recruiting - verified June 2017

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin

Condition:   Diabetes Mellitus Type 2 Platelets Reactivity Statin
Interventions:   Drug: Atorvastatin 80mg;   Drug: ALLOPURINOL 300 MG;   Drug: Atorvastatin 80mg AND allopurinol 300 mg
Sponsor:   University of Roma La Sapienza
Recruiting - verified June 2017

Empaglifozin in Early Diabetic Kidney Disease

Conditions:   Diabetic Kidney Disease;   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 25, 2017

PRuDENTE; Diabetes Prevention Via Exercise, Nutrition and Treatment

Conditions:   Diabetes Mellitus, Type 2;   Prediabetic State
Interventions:   Drug: Metformin;   Behavioral: Lifestyle intervention
Sponsors:   Instituto Nacional de Salud Publica, Mexico;   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;   Ministry of Health, Mexico City;   University of California, San Francisco
Not yet recruiting - verified June 2017

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Exenatide Injection
Sponsor:   Theracos
Active, not recruiting - verified June 2017

Frequency of Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetes Mellitus Type 2

Condition:   Diastolic Dysfunction
Intervention:  
Sponsor:   Assiut University
Not yet recruiting - verified May 2017

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Conditions:   Diabetes Mellitus, Type 2;   Kidney Function Tests
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Not yet recruiting - verified June 2017

Evaluation of Type 2 Diabetes Treatment

Condition:   Type2 Diabetes
Intervention:   Drug: Diabeton 60 MR
Sponsor:   Servier
Completed - verified April 2017

Impact of Empaglifozine on Cardiac Ectopic Fat

Condition:   Type 2 Diabetes
Intervention:   Drug: Empagliflozin 10Mg Tab
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified June 2017

Intensive Uric Acid Lowering With RDEA3170 and Febuxostat in Patients With Albuminuria

Conditions:   Hyperuricemia;   Albuminuria;   Type 2 Diabetes
Interventions:   Drug: RDEA3170 9 mg+Febuxostat 80 mg;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified June 2017

IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Ivabradine;   Other: Sham Comparator
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Not yet recruiting - verified June 2017

Utilizing Off-the-shelf Technology to Improve Diabetes Management in a Rural Population

Condition:   Diabetes
Intervention:   Behavioral: EpxDiabetes software
Sponsor:   University of Missouri-Columbia
Recruiting - verified June 2017

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Conditions:   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Interventions:   Biological: MK-5160 low dose;   Biological: MK-5160 medium dose;   Biological: MK-5160 high dose;   Biological: Glargine 0.4 U/kg;   Biological: Placebo to Glargine;   Biological: Placebo to MK-5160;   Drug: Dextrose
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2017

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

Conditions:   IGT - Impaired Glucose Tolerance;   T2D
Interventions:   Diagnostic Test: Oral Glucose Tolerance Test;   Diagnostic Test: Hyperglycemic Clamp;   Diagnostic Test: Isoglycemic Intravenous Glucose Test;   Diagnostic Test: Hyperinsulinemic Euglycemic Clamp and 2H20
Sponsor:   Yale University
Recruiting - verified March 2017

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Use of digital disease management tool
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Canagliflozin;   Drug: Canagliflozin placebo;   Drug: Semaglutide placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec;   Drug: Insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Mobile health system;   Other: E-mail reports and technical support for mHealth system
Sponsors:   University of Michigan;   Mahidol University;   John E. Fogarty International Center (FIC)
Recruiting - verified June 2017

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Condition:   Breast Cancer
Interventions:   Drug: Metformin Hydrochloride;   Other: OPC
Sponsor:   Medical University of South Carolina
Recruiting - verified June 2017

Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Not yet recruiting - verified June 2017

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and Metformin-treated Type 2 Diabetes

Condition:   Overweight and Obesity
Interventions:   Device: Gelesis200;   Device: Placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified June 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Device: Transcutaneous Electrical Nerve Stimulator (DW1330);   Device: Sham DW1330 device
Sponsor:   Taiwan Resonant Waves Research Corporation
Recruiting - verified May 2017

XIGDUO Extended Release (XR) Post Marketing Surveillance

Condition:   Adult Patients With Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2017

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified June 2017

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified June 2017

Glooko mHealth Advantage Study

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Glooko's mobile application
Sponsor:   Glooko
Recruiting - verified June 2017

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified June 2017

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin.

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Weight reduction training;   Behavioral: PPG training;   Behavioral: discrete BG feedback;   Behavioral: continuous BG feedback
Sponsors:   University of Virginia;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2017

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Metformin;   Drug: Glimepiride;   Drug: Sitagliptin
Sponsor:   Theracos
Completed - verified June 2017

Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus

Condition:   Pharmaceutical Services
Intervention:   Other: Pharmacotherapy Follow-up Care
Sponsor:   University of Sorocaba
Active, not recruiting - verified June 2017

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Sulfonylurea;   Drug: metformin;   Drug: basal insulin
Sponsor:   Sanofi
Active, not recruiting - verified June 2017

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices

Condition:   Diabetes Mellitus
Interventions:   Device: Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose;   Other: Point of Care (POC) blood glucose
Sponsors:   University of Maryland;   DexCom, Inc.
Recruiting - verified June 2017

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   Parexel;   Spandauer Damm 130;   14050;   Berlin, Germany
Recruiting - verified June 2017

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Condition:   Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Interventions:   Drug: Ipragliflozin;   Drug: metformin with pioglitazone
Sponsor:   Yonsei University
Completed - verified June 2017

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ipragliflozin
Sponsor:   Astellas Pharma Inc
Active, not recruiting - verified June 2017

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial With a 52-week Extension Phase

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Active, not recruiting - verified June 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2017

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified June 2017

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified June 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone;   Drug: SGLT2 inhibitor
Sponsor:   Sanofi
Recruiting - verified June 2017

Study to Evaluate CORT125134 in Patients With Cushing's Syndrome

Condition:   Cushing's Syndrome
Intervention:   Drug: CORT125134
Sponsor:   Corcept Therapeutics
Recruiting - verified June 2017

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

PASS to Assess Risk of Renal Injury, Hepatic Injury, Diabetic Ketoacidosis and Infections in Empagliflozin-treated Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Sulfonylurea;   Drug: DPP-4 inhibitors
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/insulin aspart;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified June 2017

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified June 2017

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Completed - verified June 2017

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Active, not recruiting - verified June 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Systematic Medical Assessment, Referral and Treatment for Diabetes Care in China Using Lay Family Health Promoters

Conditions:   Diabetes Mellitus, Type 2;   Hypertension;   Dyslipidemias
Intervention:   Behavioral: SMARTHealth Diabetes
Sponsors:   The George Institute for Global Health, China;   Global Alliance for Chronic Diseases;   National Health and Medical Research Council, Australia
Not yet recruiting - verified June 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Families Preventing Diabetes Together

Conditions:   Type 2 Diabetes;   Pediatric Obesity
Intervention:   Behavioral: Families Preventing Diabetes Together
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting - verified June 2017

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Condition:   Non Alcoholic Fatty Liver Disease
Intervention:   Drug: Empagliflozin
Sponsor:   Medanta, The Medicity, India
Active, not recruiting - verified June 2017

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Completed - verified June 2017

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/insulin aspart;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified June 2017

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Condition:   Dyslipidemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: statins;   Drug: ezetimibe;   Drug: fenofibrate;   Drug: nicotinic acid;   Drug: omega-3 fatty acids
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed - verified June 2017

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Standard of Care
Sponsors:   AstraZeneca;   Quintiles, Inc.;   Clinical Practice Research Datalink
Recruiting - verified June 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec;   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsors:   Göteborg University;   Vastra Gotaland Region
Recruiting - verified June 2017

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified June 2017

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Suglat
Sponsor:   Astellas Pharma Inc
Active, not recruiting - verified June 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified June 2017

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2017

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified June 2017

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

Condition:   Diabetic Nephropathies
Interventions:   Dietary Supplement: Calcitriol;   Drug: Losartan
Sponsors:   Weill Cornell Medical College in Qatar;   Hamad Medical Corporation;   Weill Medical College of Cornell University
Terminated - verified June 2017

Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus

Conditions:   Thrombosis;   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Primrose oil;   Dietary Supplement: Fish Oil
Sponsors:   University of Michigan;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified June 2017

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified June 2017

Mechanisms of Endothelial Dysfunction in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Biological: Blood samples
Sponsor:   University Hospital, Rouen
Completed - verified June 2017

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified June 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Condition:   Healthy Volunteer, Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: RO6799477
Sponsor:   Hoffmann-La Roche
Completed - verified June 2017

Effect of Intranasal Insulin on LH Concentrations in Man

Condition:   Hypogonadotropic Hypogonadism
Interventions:   Drug: intranasal insulin;   Drug: placebo (intranasal saline)
Sponsor:   Texas Tech University Health Sciences Center
Recruiting - verified June 2017

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   George Washington University;   AstraZeneca
Active, not recruiting - verified June 2017

Effect of Exercise on Metabolic Health

Condition:   Obesity
Intervention:   Other: Exercise
Sponsors:   University of Michigan;   American Diabetes Association
Recruiting - verified June 2017

Influence of Bariatric Surgery on Serum Levels of 26RFa

Conditions:   Diabetes;   Obesity
Intervention:   Behavioral: Meal test taking and hormones measure including 26RFa
Sponsors:   University Hospital, Rouen;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified June 2017

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified June 2017

The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family

Condition:   MODY-2 Diabetes
Intervention:   Other: OGTT
Sponsor:   Sheba Medical Center
Recruiting - verified June 2017

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

Sunshine 2 Study for Women With Diabetes

Conditions:   Diabetes;   Depression;   Quality of Life
Interventions:   Drug: Vitamin D3;   Drug: Vitamin D3 comparator
Sponsors:   Loyola University;   National Institutes of Health (NIH);   National Institute of Nursing Research (NINR)
Recruiting - verified June 2017

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified June 2017

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified June 2017

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Metformin
Sponsor:   GlaxoSmithKline
Completed - verified June 2017

Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)

Condition:   Pre-diabetes
Intervention:   Other: Pre-diabetes screening
Sponsor:   Nantes University Hospital
Active, not recruiting - verified June 2017

Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss

Conditions:   Abdominal Obesity;   Cardiovascular Diseases;   Diabetes Type 2;   Hypertension;   Overweight
Interventions:   Behavioral: Diet A;   Behavioral: Diet B;   Behavioral: Physiotherapy
Sponsors:   Lund University;   Region Skane
Completed - verified June 2017

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: SRT2104
Sponsors:   Sirtris, a GSK Company;   GlaxoSmithKline
Completed - verified June 2017

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK1362885;   Drug: GSK1362885
Sponsor:   GlaxoSmithKline
Completed - verified June 2017

The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients

Condition:   Fasting Hyperglycemia
Intervention:   Dietary Supplement: late night meal
Sponsor:   Sheba Medical Center
Completed - verified June 2017

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   Quintiles, Inc.
Recruiting - verified June 2017

Fat Cell Size in Insulin Resistance

Conditions:   Obesity;   Adipose Cell Turn Over
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 22, 2016